Search PubMed⌕ Search

Biomedical subjects

E H Cooper

Publications and source records attributed to E H Cooper.

249 records · Page 14Linked to original sources
PubMedDate not supplied

Cancer of the large intestine in man: progress and problems.

This article reviews the high incidence of colon cancer in Western countries; the contribution of cell biology and biochemistry to our knowledge of the behaviour of the disease is discussed. The use of a series of markers to obtain early evidence of metastasis and to make the prognosis is described. Some suggestions are made how to obtain improvements in the survival percentages.

Antibodies, Neoplasm↗
PubMedDate not supplied

The tumour marker CA 195 in colorectal and pancreatic cancer.

The aim of this study was to measure the serum level of the tumour markers CA 195 and CEA in patients with either colorectal or pancreatic cancer both before and at serial intervals after operation. CA 195 and CEA were measured in 199 patients with colorectal cancer and 52 patients with pancreatic cancer. The median concentrations of CA 195 were 3.0 u/ml (interquartile range 3.0-4.5 u/ml) in patients with a Dukes' stage A lesion, 5.8 u/ml (3.0-18.2 u/ml) in patients with a Dukes' stage B lesion, 6.1 u/ml (3.0-24.7 u/ml) in patients with a Dukes' stage C and 23.8 u/ml (11.1-409.0 u/ml) in patients with metastatic disease (normal range 0-7 u/ml). The median levels of CEA were 2.6 ng/ml (1.7-3.3 ng/ml) for Dukes' stage A, 3.3 ng/ml (1.7-7.2 ng/ml) for Dukes' stage B, 3.7 ng/ml (2.2-7.9 ng/ml) for Dukes' stage C and 34.5 ng/ml (13.3-289.4 ng/ml) for metastatic disease. A rising level of CA 195 or CEA after operation suggested recurrence of the tumour. In none of these patients was the recurrence operable. In patients with pancreatic adenocarcinoma, the level of CA 195 was significantly higher in patients with metastatic disease but it did not discriminate between resectable and unresectable disease. The duration of survival correlated with the initial level of CA 195 (Rs = -0.66, p less than 0.001).

Antigens, Tumor-Associated, Carbohydrate↗
PubMedDate not supplied

Neuron-specific enolase.

The clinical value of neuron-specific enolase as a marker is small cell lung cancer, neuroblastoma, melanoma and seminoma has been reviewed. The role of serum and cerebrospinal NSE in benign and malignant disease of the central nervous system is discussed.

Biomarkers↗
PubMedDate not supplied

Biochemical markers in gastrointestinal malignancies.

The authors review the role of tumor markers in distinguishing benign from malignant conditions of the digestive tract. They also discuss the value of cancer markers to stratify patients in terms of their survival probability, to detect recurrence and to monitor treatment.

Acute-Phase Proteins↗
PubMedDate not supplied

The assessment of antichymotrypsin in cancer monitoring.

A comparative study of serum antichymotrypsin, acid glycoprotein and antitrypsin levels has been made in various cancers. Antichymotrypsin (ACT) shows a non-specific elevation in metastatic cancer, and the response reflects tumour progression in a similar fashion to the other two acute phase reactant proteins. The main advantage of ACT as a marker appears to be its Normal distribution in health, and lack of phenotypic variation.

Alkaline Phosphatase↗
PubMedDate not supplied

Acute phase reactant proteins as aids to monitoring disease.

The plasma acute phase reactant proteins are a group consisting mainly of glycosialated proteins, whose levels rise in response to a wide variety of injuries. This review discusses how by considering several APRPs coincidentally the pattern of change can have a discriminant function which can be used alone or to enhance other biochemical tests, especially in the monitoring of disease.

Adult↗
PubMedDate not supplied

Serum beta 2-microglobulin in malignant and benign diseases of the stomach and pancreas.

The levels of serum beta 2-microglobulin (beta 2-m) were measured in 480 patients suffering from gastric cancer, pancreatic cancer and benign diseases of the stomach and pancreas. Elevated levels were found in both cancer and benign diseases, although they were more frequent in cancer. However, these differences did not appear to have any diagnostic significance, there was no evidence that the level of serum beta 2-microglobulin bore any relation to the prognosis in carcinoma of the stomach or in carcinoma of the pancreas.

Adolescent↗
PubMedDate not supplied

Neuron-specific enolase (NSE) in serum. Comparison of monoclonal versus polyclonal assay based on 392 blood samples.

Neuron-specific enolase (NSE) is the best described serum tumor marker for small cell lung cancer (SCLC). Almost all clinical studies carried out so far used assays involving polyclonal antibodies against NSE; the majority of the studies analyzed the samples by a RIA NSE kit. We evaluated a new monoclonal kit and compared it to the polyclonal kit. We analyzed 392 serum samples, 265 from patients with SCLC, 88 from non-small cell lung cancers (NSCLC) and 39 from children with neuroblastomas. We found a good correlation between the results of the two assays. When correlating NSE in SCLC as measured with the two assays with clinical data, we found the same sensitivity, prognostic impact and value in treatment monitoring. We conclude that the "new" monoclonal assay is a fully acceptable alternative to the "old" polyclonal assay.

Antibodies, Monoclonal↗